Asked by: Gregory Campbell (Democratic Unionist Party - East Londonderry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the reduction in the qualifying age for bowel cancer screening on detection rates in the past five years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The final roll out of this policy only concluded in April 2025. As such, NHS England has not yet made any formal assessment of the impact of lowering the age for bowel cancer screening down to 50 on detection rates.
However, when making the recommendation to extend the screening age, from 60- to 74- year olds to 50- to 74- year olds, and to replace the faecal occult blood test with the faecal immunochemical test at the current test sensitivity threshold of 120 micrograms of haemoglobin per gram of faeces, these two activities combined were estimated to nearly double the number of colorectal cancer incidences detected and mortality reduced.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of (a) reviewing and (b) increasing the level of payment provided under the Vaccine Damage Payment Scheme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I would like to reiterate my deepest sympathies to all those individuals who have experienced harm following vaccination, and to their families.
I recognise many of the concerns that campaigners have raised regarding the Vaccine Damage Payment Scheme (VDPS). Their input will shape our ongoing consideration of reforms to the scheme.
In parallel, the Department continues to work with the NHS Business Services Authority, the administrators of the VDPS, to take further steps to improve the scheme, including through processing claims at a faster rate.
I will keep Parliament updated, as appropriate.
Asked by: Peter Bedford (Conservative - Mid Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to review the 60% disability threshold requirement to qualify for the vaccine damage payment scheme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I would like to reiterate my deepest sympathies to all those individuals who have experienced harm following vaccination, and to their families.
I recognise many of the concerns that campaigners have raised regarding the Vaccine Damage Payment Scheme (VDPS). Their input will shape our ongoing consideration of reforms to the scheme.
In parallel, the Department continues to work with the NHS Business Services Authority, the administrators of the VDPS, to take further steps to improve the scheme, including through processing claims at a faster rate.
I will keep Parliament updated, as appropriate.
Asked by: Jonathan Davies (Labour - Mid Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the effectiveness of the Vaccine Damage Payment Scheme.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
I would like to reiterate my deepest sympathies to all those individuals who have experienced harm following vaccination, and to their families.
I recognise many of the concerns that campaigners have raised regarding the Vaccine Damage Payment Scheme (VDPS). Their input will shape our ongoing consideration of reforms to the scheme.
In parallel, the Department continues to work with the NHS Business Services Authority, the administrators of the VDPS, to take further steps to improve the scheme, including through processing claims at a faster rate.
I will keep Parliament updated, as appropriate.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the availability of treatment for those with Friedreich’s Ataxia.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Under the UK Rare Diseases Framework, the Government is working to improve access to specialist care, treatments, and drugs across all rare conditions. In February, we published the fourth England action plan reporting on progress.
Following extensive consultation, NHS England has revised the national service specification for specialised neurology, which now includes an annex providing greater clarity for neurology sub-specialties. This includes the categories of both movement disorders and neurogenetics into which Friedreich’s Ataxia falls. Every specialised National Health Service neurology centre could and should see patients with Friedreich’s Ataxia.
Although Skyclarys (omaveloxolone) is now licensed for those aged 16 years old and over, following an update from the company, Biogen, the National Institute for Health and Care Excellence (NICE) has had to terminate its appraisal of this medicine as the company has withdrawn its evidence submission. NICE will review its decision if the company decides to make a new submission. Further information is available at the following link:
https://www.nice.org.uk/guidance/TA1061
To avoid the possibility of creating a way to circumvent the appraisal process, NHS England is unable to fund medicines where companies have not engaged with NICE.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) promote earlier detection of mouth cancer, (b) ensure (i) dentists, (ii) GPs and (iii) other frontline health professionals are trained to identify early warning signs and (c) reduce the time taken to (A) diagnose and (B) refer patients for treatment for mouth cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We know that cancer incidence, including mouth cancer incidence, is increasing. We know that more needs to be done to improve outcomes for patients with mouth cancer, including raising awareness of signs and symptoms and focusing on prevention, such as the introduction of the Tobacco and Vapes Bill.
Our forthcoming National Cancer Plan will have patients at its heart, and it will include further details on how we will speed up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately drive up this country’s cancer survival rates.
To support earlier and faster cancer diagnosis, we are now delivering additional checks, tests and scans at 170 community diagnostic centres.
Additionally, to help increase early detection of cancer, the Government has recently launched Jess’s Rule, an initiative that asks general practitioners (GPs) to think again if, after three appointments, they have been unable to diagnose a patient, or their symptoms have escalated.
We are also investing an additional £889 million in general practice, bringing total spend on the GP Contract to £13.2 billion in 2025/26. This will help to ensure we have a well-trained and well-equipped primary care service that can take the time to provide quality care to patients around the country.
Dentists and other dental professionals, including hygienists, routinely check the soft tissues of a patient’s mouth for signs of cancer during dental visits and as part of the check-up will make an assessment and record an individual’s oral cancer risk. Dentists will prioritise patients at a higher risk of oral cancer for more frequent recall and review in line with National Institute for Health and Care Excellence guidance.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of trends in the level of mouth cancer in the last ten years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We know that cancer incidence, including mouth cancer incidence, is increasing. We know that more needs to be done to improve outcomes for patients with mouth cancer, including raising awareness of signs and symptoms and focusing on prevention, such as the introduction of the Tobacco and Vapes Bill.
Our forthcoming National Cancer Plan will have patients at its heart, and it will include further details on how we will speed up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately drive up this country’s cancer survival rates.
To support earlier and faster cancer diagnosis, we are now delivering additional checks, tests and scans at 170 community diagnostic centres.
Additionally, to help increase early detection of cancer, the Government has recently launched Jess’s Rule, an initiative that asks general practitioners (GPs) to think again if, after three appointments, they have been unable to diagnose a patient, or their symptoms have escalated.
We are also investing an additional £889 million in general practice, bringing total spend on the GP Contract to £13.2 billion in 2025/26. This will help to ensure we have a well-trained and well-equipped primary care service that can take the time to provide quality care to patients around the country.
Dentists and other dental professionals, including hygienists, routinely check the soft tissues of a patient’s mouth for signs of cancer during dental visits and as part of the check-up will make an assessment and record an individual’s oral cancer risk. Dentists will prioritise patients at a higher risk of oral cancer for more frequent recall and review in line with National Institute for Health and Care Excellence guidance.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the (a) number of referrals and (b) time taken to treat people with heart valve disease in each region.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Cutting elective care waiting times, including for cardiology services, is a key priority for the Government. The national waiting list for cardiology services has fallen by 59,307 since this Government came into office, with an increase in the proportion waiting less than 18 weeks, from 60.2% to 62.4%. But we know there is much more work to be done.
Cardiology is identified as a top priority for reform in our Elective Reform Plan, published in January 2025. Specific actions being taken to reform cardiology include increasing specialist input earlier in care pathways, developing standard pathways for common outpatient presentations such as palpitation, and increasing timely access to cardiac diagnostic tests, including through “straight to test” pathways.
To accelerate progress towards the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework in 2026. The Department and NHS England are engaging widely throughout its development to ensure that we prioritise ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care.
My Rt. Hon. Friend, the Chancellor of the Exchequer, announced £600 million in the October statement to reduce diagnostic waiting lists, supporting new and expanded community diagnostic centres (CDCs), upgraded hospital diagnostic equipment, and digital diagnostic capabilities. NHS England's digital investments, including using artificial intelligence for cardiac imaging, have accelerated cardiology test reporting. From July 2024 to September 2025, CDCs performed 312,049 echocardiography and 281,869 electrocardiography tests, with many centres adopting innovative cardiac pathways to speed diagnosis and treatment, including for women.
The Government is committed to prioritising women’s health as we build a National Health Service fit for the future. We know that women deserve better, which is why we are delivering our commitment that never again will women’s health be neglected. The 2022 Women’s Health Strategy identified many important issues, including cardiology, which remain valid, so we now need to align the strategy with the 10-Year Health Plan and identify areas where we need to go further. That is why we are updating the Women’s Health Strategy, to assess the progress that has been made so far and to continue progressing delivery.
Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure access to (a) diagnostic and (b) treatment options for women with heart valve disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Cutting elective care waiting times, including for cardiology services, is a key priority for the Government. The national waiting list for cardiology services has fallen by 59,307 since this Government came into office, with an increase in the proportion waiting less than 18 weeks, from 60.2% to 62.4%. But we know there is much more work to be done.
Cardiology is identified as a top priority for reform in our Elective Reform Plan, published in January 2025. Specific actions being taken to reform cardiology include increasing specialist input earlier in care pathways, developing standard pathways for common outpatient presentations such as palpitation, and increasing timely access to cardiac diagnostic tests, including through “straight to test” pathways.
To accelerate progress towards the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework in 2026. The Department and NHS England are engaging widely throughout its development to ensure that we prioritise ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care.
My Rt. Hon. Friend, the Chancellor of the Exchequer, announced £600 million in the October statement to reduce diagnostic waiting lists, supporting new and expanded community diagnostic centres (CDCs), upgraded hospital diagnostic equipment, and digital diagnostic capabilities. NHS England's digital investments, including using artificial intelligence for cardiac imaging, have accelerated cardiology test reporting. From July 2024 to September 2025, CDCs performed 312,049 echocardiography and 281,869 electrocardiography tests, with many centres adopting innovative cardiac pathways to speed diagnosis and treatment, including for women.
The Government is committed to prioritising women’s health as we build a National Health Service fit for the future. We know that women deserve better, which is why we are delivering our commitment that never again will women’s health be neglected. The 2022 Women’s Health Strategy identified many important issues, including cardiology, which remain valid, so we now need to align the strategy with the 10-Year Health Plan and identify areas where we need to go further. That is why we are updating the Women’s Health Strategy, to assess the progress that has been made so far and to continue progressing delivery.
Asked by: Munira Wilson (Liberal Democrat - Twickenham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of existing stroke treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service is continuing to improve stroke services, but we recognise there is more to do.
The National Stroke Service Model and the National service model for an integrated community stroke service set out an evidence-based pathway for joined-up stroke care throughout the patient journey.
The NHS is committed to delivering thrombolysis to twice as many patients through the Thrombolysis in Acute Stroke Care (TASC) initiative. The TASC initiative unites stroke teams to use quality improvement methods to reduce delays and deliver faster, safer, more patient-centred care.